Roger that Jesse. Keiturn, looking forward, anyone who is interested in making a protein, lets say it might be a 'bio-similar' to a current product whose patent expires in a few years, would surely be interested in a manufacturing process which provides a much lower capital cost for the factory (goats vrs. a cell-culture plant) and a lower cost of production, perhaps in the range of 1/3 to 1/10 that of cell culture. Also, the capital requirement for a 'goat based factory' is scalable, meaning you can expand your capacity in small increments, compared to a cell culture based factory.
Regarding their own products, there are many plasma proteins which do not express well in culture and are available only from donated blood and often in limited amounts, if at all. GTC has several opportunities in this space alone. Monoclonal antibodies which require high volumes are another example where this 'platform' offers a real advantage. Indeed, I think one of the challenges for the company is to be careful in deciding what to pursue as they can't do everything at once. Hence the the recent hires which I regard as reassuring in this regard and a significant statement about how this technology is now perceived in the industry.
News 
Market Data 
Discover 
